The combination of atezolizumab, an anti–PD-L1 inhibitor, with bevacizumab was compared with sorafenib as first-line treatment of unresectable HCC in the phase 3 IMbrave150 trial.15 The combination was superior to sorafenib in OS and progression-free survival (PFS), the co–primary end points (12-month OS, 67.2% vs 54.6%; HR, 0.58; 95% CI, 0.42-0.79; P < .001; median PFS, 6.8 months vs 4.3 months; HR, 0.59; 95% CI, 0.47-0.76; P < .001).15,16 Based on the IMbrave150 findings, the combination of atezolizumab plus bevacizumab has replaced sorafenib as the standard of care for unresectable HCC. Here, CD274 is linked to hepatocellular carcinoma.